All In Biotech

Drug Trial Radar · NCT05148286

Albumin and Crystalloid Administration in Septic Shock

Albumin and Crystalloid Administration in Septic Shock (ALCAMIST): Multi-center, Open Labelled Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 2,426 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,426

Planned (sponsor's estimate)

Start

Jan 17, 2022

Primary completion

Sep 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Asan Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Samsung Medical Center; Gangnam Severance Hospital; Chungnam National University Hospital; Seoul National University Hospital; Seoul National University Bundang Hospital; SMG-SNU Boramae Medical Center; Hanyang University; Korea University Ansan Hospital
First posted
Dec 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The current guideline emphasizes fluid resuscitation as the mainstay of initial management for septic shock. Albumin has the oncotic activity to maintain intravascular volumes with additional beneficial properties in sepsis. Prior studies showed that the replacement of albumin might have survival advantages in patients with septic shock. The investigators aim to assess whether the early administration of albumin with crystalloid as initial fluid resuscitation improves survival in patients with septic shock compared to resuscitation without albumin.

Conditions

  • Septic Shock

Interventions

  • TreatmentDrug

    For the treatment group, 200cc of 20% human albumin with 15 cc per kg of crystalloid will be administered over 1\~2h for initial fluid resuscitation. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.

  • PlaceboDrug

    For the control group, 30 cc per kg of crystalloid will be administered according to the usual practice. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 28-day all-cause mortalityTime frame: 28-days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.